Modulating renal lymphatics to regulate blood pressure
Inventors
Mitchell, Brett • Kim, Dongin • Nabity, Mary • Rutkowski, Joseph
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12521427-B2
Publication Date
2026-01-13
Expiration Date
Abstract
The present invention relates to a method for reducing blood pressure by stimulating lymphatic vessel growth and/or lymphangiogenesis in the kidneys.
Core Innovation
The invention relates to renal-lymphatic modulation for blood pressure control by inducing renal lymphangiogenesis. It provides a renal targeting mesoscale nanoparticle drug delivery vehicle that encapsulates VEGF-C with a c156s mutation and delivers the composition to the kidney. In a subject having high blood pressure, treatment with the renal targeting mesoscale nanoparticle under conditions sufficient to induce renal lymphangiogenesis results in lower blood pressure after treatment.
The described approach targets renal lymphatic vessel growth by using VEGF-C with a c156s mutation, where VEGF-C c156s is described as binding specifically to VEGFR-3. The content further contrasts negligible liver delivery with kidney delivery, and frames selectivity in terms of a kidney versus liver drug delivery ratio. In this context, renal lymphatic expansion and increased renal lymphatics are provided as expected outcomes associated with reduced hypertension, including salt-sensitive hypertension.
The disclosure also frames the invention in terms of renal lymphangiogenesis induction relative to hypertension status, and supports the concept with renal fluid/pressure modeling using a mathematical model. It includes example nanoparticle development and a framework for monitoring renal lymphatics and blood pressure readouts alongside tracking delivery. The disclosed signaling emphasis is on renal lymphangiogenesis induced by the VEGF-C c156s payload delivered via kidney-targeting nanoparticles.
Claims Coverage
The partial claims include two independent methods: (1) inducing renal lymphangiogenesis in a subject with high blood pressure and achieving reduced blood pressure after treatment, and (2) lowering blood pressure in a subject with hypertension through renal lymphangiogenesis induced by a renal targeting mesoscale nanoparticle delivering VEGF-C with a c156s mutation.
Renal targeting mesoscale nanoparticle encapsulating VEGF-C with a c156s mutation delivered to the kidney
A method that provides a drug delivery vehicle comprising a renal targeting mesoscale nanoparticle encapsulating VEGF-C with a c156s mutation, wherein the drug delivery vehicle delivers the composition to the kidney.
Inducing renal lymphangiogenesis to achieve lower blood pressure in a subject with high blood pressure
Treating a subject having high blood pressure by administering the renal targeting mesoscale nanoparticle drug delivery vehicle under conditions such that renal lymphangiogenesis is induced in one or more kidneys, wherein blood pressure is lower after treatment.
Lowering blood pressure by inducing renal lymphangiogenesis with VEGF-C c156s kidney-delivered nanoparticles
A method of lowering blood pressure that provides a renal targeting mesoscale nanoparticle encapsulating VEGF-C with a c156s mutation delivered to the kidney and administering the vehicle under conditions such that renal lymphangiogenesis is induced in one or more kidneys, resulting in lower blood pressure after treatment.
Across both independent claims, the core coverage centers on a renal targeting mesoscale nanoparticle drug delivery vehicle encapsulating VEGF-C with a c156s mutation delivering the payload to the kidney, treatment conditions that induce renal lymphangiogenesis in one or more kidneys, and achieving lower blood pressure after induction in subjects with hypertension or high blood pressure.
Stated Advantages
Lower blood pressure after inducing renal lymphangiogenesis in one or more kidneys.
Induction of renal lymphangiogenesis, described in terms of renal lymphatics and renal lymphatic expansion.
Reduced hypertension, including salt-sensitive hypertension.
Improved delivery selectivity by keeping liver delivery negligible and delivering more drug to the kidney than to the liver.
Documented Applications
Renal-lymphatic modulation for blood pressure control by inducing renal lymphangiogenesis in subjects with high blood pressure or hypertension, including salt-sensitive hypertension.
Interested in licensing this patent?